Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial - Herbst, R S; Baas, P; Kim, D W (Lancet, 2016)
10.1016/S0140-6736(15)01281-7